Sarepta Therapeutics (SRPT) Data Update Does Not Imply Meaningful Change - Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Martin Auster reiterated a Neutral rating and $167.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
